# US 2025/0144100 A1 · Pharmaceutical composition comprising ibrutinib

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144100 A1
- Document ID: US20250144100A1
- Status: Published application
- Kind: A1
- Application number: 18/717,130
- Filed: 2022-12-06
- Published: 2025-05-08
- Earliest claimed: 2021-12-10
- Assignees: Synthon BV
- Applicants: Synthon B.V.
- Inventors: Marta VIVANCOS MARTINEZ; Lisardo ALVAREZ FERNANDEZ; Rohit KUMAR
- Web page: https://patentgrep.com/patent/US20250144100A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2095: {Tabletting processes}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a tablet composition comprising Ibrutinib and one ore more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL), Waldenström's macroglobulinaemia (WM) and chronic graft versus host disease (cGVHD).

## Claims

### Claim 1

A high load tablet comprising from 60 to 85% by weight of Ibrutinib relative to the total weight of the tablet, from 1.5% to 3% by weight of sodium stearyl fumarate relative to the total weight of the tablet, and one or more pharmaceutically acceptable excipients.

### Claim 2 (depends on 1)

The tablet according to claim 1, wherein the amount of sodium stearyl fumarate is from 1.8% to 2.2% by weight relative to the total weight of the tablet.

### Claim 3 (depends on 1)

The tablet according to claim 1, wherein the Ibrutinib has a particle size distribution D90 is less than 100 micrometers when measured by laser diffraction analysis.

### Claim 4 (depends on 1)

The tablet composition according to claim 1, wherein the pharmaceutically acceptable excipients are chosen from one or more fillers, binders, disintegrants, glidants and surfactants.

### Claim 5 (depends on 1)

The tablet according to claim 1, comprising:
a) Ibrutinib in an amount from 60 to 85% by weight;
b) Sodium stearyl fumarate in an amount from 1.5 to 3% by weight;
c) One or more fillers in an amount from 10 to 30% by weight;
d) One or more binders in an amount from 0 to 5% by weight;
e) One or more disintegrants in an amount from 2 to 15% by weight;
f) One or more glidants in an amount from 0.25 to 1.0% by weight; and
g) One or more surfactants in an amount from 0.5 to 3% by weight;
all relative to the total weight of the tablet.

### Claim 6 (depends on 1)

The tablet according to claim 1 prepared by wet or dry granulation.

### Claim 7 (depends on 6)

The tablet according to claim 6 prepared by wet granulation.

### Claim 8 (depends on 6)

The tablet according to claim 6, wherein the Ibrutinib is contained intragranularly in said tablet.

### Claim 9 (depends on 6)

The tablet according to claim 6, wherein said sodium stearyl fumarate is contained extragranularly in said tablet.

### Claim 10 (depends on 5)

The tablet according to claim 5, wherein said tablet has an intragranular component and an extragranular component; and wherein said Ibrutinib is present in the intragranular component and said sodium stearyl fumarate is present in the extragranular component.

### Claim 11 (depends on 10)

The tablet according to claim 10, wherein the amount of sodium stearyl fumarate is from 1.8% to 2.2% by weight relative to the total weight of the tablet.
